Bicycle Therapeutics (BCYC) Net Equity Issued and Repurchased (2021 - 2024)

Bicycle Therapeutics (BCYC) has 3 years of Net Equity Issued and Repurchased data on file, last reported at -$979000.0 in Q3 2024.

• Quarterly Net Equity Issued and Repurchased fell 105.05% year-over-year to -$979000.0 in Q3 2024, while the trailing twelve-month figure through Dec 2024 was $18.4 million (down 46.15% YoY) and the FY2024 annual result came in at $544.1 million, up 118.22% from the prior year.
• Net Equity Issued and Repurchased slipped to -$979000.0 in Q3 2024, from $10000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $188.4 million in Q4 2021 to a low of -$979000.0 in Q3 2024.
• A 3-year average of $35.9 million and a median of $12.1 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 105.05% in 2024, down 105.05% in 2024.
• Tracing BCYC's Net Equity Issued and Repurchased over 3 years: stood at $188.4 million in 2021, then plunged by 99.99% to $10000.0 in 2023, then plunged by 9890.0% to -$979000.0 in 2024.
• The last three Net Equity Issued and Repurchased figures came in at -$979000.0 (Q3 2024), $10000.0 (Q4 2023), and $19.4 million (Q3 2023), per Business Quant data.